India's First AI Blood Testing Device Gets Government Backing

On August 18, 2025, the Technology Development Board (TDB)—under India’s Department of Science and Technology—entered into an agreement with Primary Healthtech Pvt. Ltd., a New Delhi-based company founded by IIT Guwahati alumni, for the development of an IoT-enabled, AI/ML-powered, point-of-care blood testing device aimed at making diagnostics affordable and accessible in primary healthcare settings.

 

The device, called Mobilab, is a portable, battery-operated clinical chemistry analyzer, capable of testing over 25 health parameters, including indicators for kidney, liver, heart health, vitamins, and cancer. It has already been trialed with 10,000 patients, holds a CDSCO manufacturing license, and includes a patented “transmittance-based system/kit for point-of-care quantification” transferred from IIT Guwahati, along with six additional patent applications.

 

 

The upgraded M1 prototype will be enhanced to handle five simultaneous tests, reducing wait time and enabling commercial-scale manufacturing. The tests will include:

 

Haemoglobin

 

Creatinine

 

Bilirubin

 

Cholesterol

 

Triglycerides

 

Uric acid

 

Glucose

 

Gamma-glutamyl transferase (GGT)

 

 

This initiative underscores India’s strategic push for Atmanirbhar Bharat—fostering indigenous innovation in medical technology.

 

As stated by Secretary Rajesh Kumar Pathak (TDB): “Ensuring quality healthcare access in rural and remote regions is a national priority. This project not only addresses affordability and accessibility but also demonstrates India’s capability in developing indigenous, AI-powered diagnostic solutions for primary healthcare.”

Primary Healthtech sees TDB’s support as a major push to transition from lab innovation to large-scale deployment, aiming to bridge healthcare gaps in rural and underserved areas.

Source